NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Price Target & More

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.26. The biotechnology company earned $56.16 million during the quarter, compared to analysts' expectations of $43.02 million. Ligand Pharmaceuticals had a net margin of 31.40% and a return on equity of 19.10%. The business's revenue was up 91.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.57 EPS. View Ligand Pharmaceuticals' Earnings History.

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Ligand Pharmaceuticals.

Ligand Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, June, 27th. The company provided earnings per share (EPS) guidance of $6.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.05. The company issued revenue guidance of $226 million, compared to the consensus revenue estimate of $188.08 million.Ligand Pharmaceuticals also updated its Q2 guidance to $2.32-2.37 EPS.

6 equities research analysts have issued 12 month target prices for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $245.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $177.60 in the next year. This suggests that the stock has a possible downside of 23.4%. View Analyst Ratings for Ligand Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Ligand Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX) and SAGE Therapeutics (SAGE).

Media stories about LGND stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a coverage optimism score of 0.15 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (2.36%), Summit Creek Advisors LLC (0.24%), Fisher Asset Management LLC (0.21%), Creative Planning (0.05%), Covenant Asset Management LLC (0.05%) and Bank of Montreal Can (0.04%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Municipal Employees Retirement System of Michigan, Fisher Asset Management LLC, Fortaleza Asset Management Inc. and Bank of Montreal Can. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.

LGND stock was bought by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Covenant Asset Management LLC, Boston Advisors LLC, Hartford Investment Management Co., Creative Planning, Cim LLC, World Asset Management Inc and Fred Alger Management Inc.. View Insider Buying and Selling for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $231.88.

Ligand Pharmaceuticals has a market capitalization of $4.94 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]